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Although Smad signalling is known to play a tumour suppressor role, it has been shown to play a prometastatic function also in breast
cancer and melanoma metastasis to bone. In contrast, mutation or reduced level of Smad4 in colorectal cancer is directly correlated
to poor survival and increased metastasis. However, the functional role of Smad signalling in metastasis of colorectal cancer has not
been elucidated. We previously reported that overexpression of Smad7 in colon adenocarcinoma (FET) cells induces tumorigenicity
by blocking TGF-b-induced growth inhibition and apoptosis. Here, we have observed that abrogation of Smad signalling by Smad7
induces liver metastasis in a splenic injection model. Polymerase chain reaction with genomic DNA from liver metastases indicates
that cells expressing Smad7 migrated to the liver. Increased expression of TGF-b type II receptor in liver metastases is associated with
phosphorylation and nuclear accumulation of Smad2. Immunohistochemical analyses have suggested poorly differentiated spindle cell
morphology and higher cell proliferation in Smad7-induced liver metastases. Interestingly, we have observed increased expression
and junctional staining of Claudin-1, Claudin-4 and E-cadherin in liver metastases. Therefore, this report demonstrates, for the first
time, that blockade of TGF-b/Smad pathway in colon cancer cells induces metastasis, thus supporting an important role of Smad
signalling in inhibiting colon cancer metastasis.
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Metastasis is the major cause of cancer morbidity and mortality,
and accounts for 90% of cancer deaths. Despite the fact that
metastasis ultimately kills the host, the mechanisms leading to
tumour invasion and metastasis have been less characterized than
those resulting in tumour initiation. Cancer development and
metastasis is a multistep process that involves local tumour growth
and invasion followed by dissemination to, and re-establishment
at, the distant sites (Liotta et al, 1991; Oft et al, 2002). There is
compelling evidence indicating that TGF-b has complex roles in
tumour suppression and progression that are context- and stage-
dependent. Therefore, elucidating the molecular pathways essen-
tial for tumour metastasis is a higher priority in the pathobiology
of cancer to design small molecule drugs.
Family members of TGF-b initiate signalling from the cell
surface by binding to a heteromeric complex of two distinct but
related serine/threonine kinase receptors. Binding of the ligand to
the type II receptor (TbRII) results in recruitment and phosphor-
ylation of the type I receptor (TbRI). After being activated, TbRI
propagates the signal to a family of intracellular signal mediators
known as Smads. Smad proteins are classified according to their
structure and function in signalling by TGF-b family members.
Receptor-regulated Smads, Smad2 and Smad3, are phosphorylated
and activated by TbRI. Then they form complexes with common
Smad (Smad4) and translocate to the nucleus for regulating the
expression of target genes. Given the involvement of TGF-b in
regulation of cellular homoeostasis, it is expected that there are also a
number of feedback mechanisms regulating this process. The activity
of the inhibitory Smad, Smad7, is regulated at many levels, suggesting
that they serve as key regulators for fine-tuning the responses to
TGF-b signalling. Smad7 normally resides in the nucleus and moves
to the cytoplasm in response to TGF-b.T G F - b not only enhances the
expression of Smad7 transcription but also mobilises a pre-existing
nuclear pool of Smad7 to inhibit TGF-b receptors (Itoh et al, 1998).
Smad7 also interfere with TGF-b/Smad signalling through the
recruitment of E3 ubiquitin ligases leading to the degradation of
receptors and through the interaction with GADD34 that inactivate
TbRI (Shi et al, 2004). Smad7 expression can also be induced by
other signalling inputs, which interfere with TGF-b signalling.
Genes involved in oncogenic pathways are generally classified as
either tumour suppressors or promoters, depending on their
function in regulating cell growth, differentiation and death. TGF-
b and its downstream signal transducers are well documented for
such paradoxical characters. Genetic manipulation of the TGF-b
pathway in tumour cells and experimental animal models validated
the metastasis-promoting function of TGF-b in the late stage of
cancer progression (Letterio, 2005). Carcinogen-induced tumours
that develop in TGF-b haploid mice often maintain the wild-type
TGF-b allele and these tumours in fact produce higher level of
TGF-b than tumours from the wild-type mice (Tang et al, 1998).
However, after development, the transgenic tumours rapidly
acquire a spindle cell phenotype, overexpress TGF-b, and
metastasise (Cui et al, 1996). These observations have led to the
speculations that during cancer progression, TGF-b may reverse its
role from an inhibitor of tumour growth to a tumour promoter
(Reiss and Barcellos-Hoff, 1997; Massague et al, 2000; Derynck et al,
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s2001). Although complete or partial loss of TGF-b signals
is permissive for early stages of tumour development, active
TGF-b signalling with selective loss of growth inhibitory response
of TGF-b may be advantageous for the progression and metastasis
of cancer.
The tumour suppressor Smad pathway has been shown to
mediate the prometastatic function of TGF-b in the development
of breast cancer bone metastasis (Kang et al, 2005). In addition,
blockade of Smad pathway by overexpression of the inhibitory
Smad, Smad7 impairs bone and lung metastases (Azuma et al,
2005; Javelaud et al, 2007). In contrast, Smad4 mutation and its
reduced level in colorectal cancer are directly correlated to poor
prognosis and increased metastasis (Miyaki et al, 1999). Further-
more, upregulation of Smad7 in colorectal cancer has been
correlated with poor survival (Korchynskyi et al, 1999). However,
nothing is known about the functional role of Smad signalling in
colorectal cancer metastasis to the liver. The purpose of this study
is to understand the stage-specific duality of TGF-b and Smad
function, and the molecular mechanism underlying the role of
Smad7 in the metastasis of colon cancer. In an experimental model
of colon cancer liver metastasis, we have shown that the stable
expression of Smad7 enhances liver metastasis. We have observed
a diffuse positive Ki67 staining and poorly differentiated spindle
cell morphology in the liver metastases. The expression of
junctional proteins is increased in the liver metastases, the
expression of some of which has been shown to be elevated in
the metastases of human cancers. Our data provide the
first evidence that Smad signalling plays a protective role in
TGF-b-induced colorectal cancer metastasis.
MATERIALS AND METHODS
Cell lines, reagents and antibodies
FET cells, vector control clone and Smad7 clones in FET cells that
overexpressed Smad7 were described previously (Halder et al,
2005). The TGF-b was purchased from R&D Systems (Minneapolis,
MN, USA), antibodies for Smad2, Smad3, Claudin-1, Claudin-4
and Claudin-7 were purchased from Zymed Laboratories Inc.
(San Francisco, CA, USA). Anti-TbRII, anti-Smad4, anti-p21
Cip1,
anti-p27
Kip1, anti-p53, anti-Cdk2, anti-Cdk4, anti-Cyclin D1, ERK and
anti-Rb antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and anti-phospho-Smad2, anti-phospho-ERK,
anti-phospho-Rb, anti-phospho-AKT and AKT antibodies were pur-
chased from Cell Signaling (Danvers, MA, USA). Anti-b-actin antibody
was purchased from Sigma Biochemicals (St Louis, MO, USA).
Analysis of liver metastasis in mice
Parental FET cells, vector control clone and three stable Smad7
clones (#2, #6 and #15) were assayed for metastasis in 5- to 6-week-
old athymic nude mice using splenic injection model as described
previously (Buchanan et al, 2006). Cells (5 10
6) from each cell
line was injected with a 27.5-gauge needle into the spleen after
pulling out through the incision made in the abdomen in a sterile
condition. The spleen was removed by electrocautery and
homoeostasis was assured. The area was thoroughly irrigated with
warm sterile water and the abdominal cavity was closed in
appropriate layers by using a 6–0 prolene suture. Thirty-three
days after surgery, mice were sacrificed and the livers were
obtained from mice. Liver weight was determined, and a portion of
tumour area or a corresponding normal liver area was collected in
a cassette and fixed overnight in 4% paraformaldehyde, stored in
70% ethanol and then processed for immunohistochemical (IHC)
studies. The other portion of liver was stored at  801C after
immediate freezing in liquid nitrogen and used for western blot
and PCR analyses.
Immunohistochemistry
Paraffin-embedded blocks were prepared from liver metastases
and normal liver of mice injected with parental or vector control
cells. A 5mm thick serial section for each slide was fixed with 20%
xylene for 20min, washed with 100 and 95% ethanol for 10min
and finally washed with water. A standard IHC method was applied
to stain the slides for hematoxylin and eosin (H&E), Ki67, Tunnel,
phospho-Smad2, E-cadherin, Claudin-1 and Claudin-4.
Western blot analysis
Lysates from normal liver and Smad7-mediated liver metastases
were prepared according to the method as described previously
(Halder et al, 2005). Briefly, liver tissue samples were cut into small
pieces, homogenized by sonication for 20s in lysis buffer containing
protease inhibitor cocktail and then centrifuged at 14000r.p.m. for
20min at 41C. Protein concentrations of clear lysates were measured
using the Bio-Rad Protein Assay kit (BioRad, Hercules, CA, USA).
Equal amount of each lysate was analysed for western blotting with
antibodies against Smad7, TbRII, phospho-Smad2, Smad2, Smad3,
Smad4, phospho-AKT, AKT, phospho-ERK, ERK, E-cadherin,
b-catenin, ZO-1, Claudin-1, Claudin-4, Claudin-7, nm23, p53, uPA,
p21
Cip1,p 2 7
Kip1, Cdk2, Cdk4, Cyclin D1, phospho-Rb and Rb. b-Actin
a n t i b o d yw a su s e da sl o a d i n gc o n t r o l .
PCR analysis
Genomic DNA was extracted from cell lines and liver metastases
using standard genomic DNA isolation protocol. Primers for
hygromycin-specific gene were used for PCR analyses (forward:
50-ATGGACGACACCGTCAGTG-30 and reverse: 50-GTCAAC
CAAGCTCTGATAGAG-30). Polymerase chain reaction was per-
formed using 2.5ml( B100ng) of DNA, 0.5U Taq DNA
polymerase, 200mM dNTPs and 10pmol of each primer. Poly-
merase chain reaction was carried out by initial denaturation at
941C for 3min followed by 30 cycles; each cycle has 941C for 45s,
521C for 45s and 721C for 1min.
RESULTS
Stable expression of Smad7 induces liver metastasis in
nude mice
The role of Smad pathway in TGF-b-mediated metastasis is
controversial. We demonstrated previously that Smad7 induces
tumorigenicity in colon tumour-derived FET cells by blocking
TGF-b-induced growth inhibition and apoptosis (Halder et al,
2005). In colorectal cancer, patients with impaired Smad signalling
show poor prognosis and increased metastasis, whereas in mouse
model of breast cancer (Kang et al, 2005) and melanoma
metastasis to bone (Javelaud et al, 2007), Smad pathway plays a
prometastatic role. These apparently contradictory results regard-
ing the role of Smad pathway in metastasis prompted us to test
whether inhibition of Smad pathway by Smad7 induces invasion
and metastasis of colon cancer cells. For this purpose, we have
used splenic injection model of liver metastasis with colon
adenocarcinoma-derived FET cells that stably express functional
Smad7 (Halder et al, 2005). The FET cells are non-tumorigenic and
highly responsive to TGF-b. We have injected parental FET cells,
one vector control clone and three Smad7-expressing clones into
the spleen of athymic nude mice, and the liver mets were obtained
by dissecting the mice 33 days after injection (Figure 1A). We
observed that 17 out of 18 control mice did not show any
metastasis in the liver (Figure 1B). Interestingly, mice injected with
all three Smad7 clones developed liver metastases. We compared
the size and morphology of livers between mice injected with
control cells and stable Smad7 clones. Interestingly, Smad7 clones
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sdeveloped aggressive liver metastases with increased liver size as
compared with vector control liver (Figure 1C). To further test
whether the liver metastasis is due to the splenic injection of
Smad7 stable cells that are migrated to the liver, we performed
PCR with genomic DNA using primers that amplify hygromycin
gene in the backbone vector of Smad7 expression construct. We
observed 345bp PCR product in Smad7-induced liver metastases,
but not in the livers of mice injected with parental FET and vector
control cells (Figure 1D, right pannel). In a parallel experiment,
PCR amplification was performed using genomic DNA from FET
cells, vector control clone and three stable Smad7 clones.
Polymerase chain reaction product was observed in the genomic
DNA from control vector and Smad7 stable cells, but not in
parental FET cells (Figure 1D, top left panel). We further verified
the expression of exogenous Smad7 in Smad7-induced metastases
by western blot analyses, using lysates from livers of mice injected
with parental FET cells and a vector control clone as well as liver
metastases from mice injected with stable Smad7 clones
(Figure 1D, bottom panel). These results suggest that only Smad7
overexpressing FET cells go to the liver, survive and produce
metastasis. Taken together, these results suggest that blockade of
TGF-b/Smad pathway in these cells by overexpressing Smad7
induces liver metastasis.
Regulation of Smad and non-Smad pathways in
Smad7-induced liver metastases
The TGF-b signalling is known to be activated in advanced stage of
tumour progression including invasion and metastasis. To verify
whether TGF-b signal mediators are affected in Smad7-induced
liver metastasis, we performed western blot analyses using lysates
from livers of mice injected with vector control clones as well as
liver metastases from mice injected with stable Smad7 clones. We
observed higher levels of TbRII in liver metastases obtained from
mice injected with Smad7-expressing clones compared with that
from control mice (Figure 2A). We further verified whether
increased levels of TbRII in liver metastases affect the downstream
Smad signalling. Interestingly, we observed increased phosphory-
lation of Smad2 in Smad7-induced liver metastases when com-
pared with that in the livers from vector control clones-injected
mice (Figure 2A). However, the levels of total Smad2, phospho-
Smad3 (data not shown), total Smad3 and Smad4 remained
unchanged irrespective of metastasis (Figure 2A). In an attempt to
test whether any of the non-Smad pathways are activated in the
liver metastases, we observed increased phosphorylation of AKT
and ERK in liver metastases from mice inoculated with Smad7-
expressing cells when compared with the mice inoculated with
vector control clones (Figure 2B). However, the phosphorylation of
p38 MAPK and c-Jun was unchanged (data not shown). These
results suggest that Smad7 induces liver metastasis through the
activation of TGF-b signalling.
Expression profile of proteins in liver metastases including
junctional and cell cycle regulatory proteins
During tumour development and metastasis the expression of
adherens junction and tight junction proteins are aberrantly
expressed or delocalised, and cells become motile and metastasise
into the target organs. Although contradictory, the level of
expression of E-cadherin and catenins has been shown to be
enhanced in metastatic lesions (Imai et al, 2004; Hung et al, 2006).
Some of the tight junction proteins including Claudin-1 (Dhawan
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Figure 1 Stable expression of Smad7 induces liver metastasis of colon adenocarcinoma (FET) cells after splenic injection in athymic nude mice. (A) Cells
from each pool of parental FET, vector control and Smad7 overexpressing cells were injected into spleen of athymic nude mice. Mice were sacrificed 33 days
after injection, liver tissues were separated and pictures were taken. (B) Represents total number of mice in each group used for splenic injection and total
number of mice showing liver metastases. The average body weight and the average weight of liver tissues from each group with respective standard
deviation were shown. (C) The graph shows the average of the ratio of liver weight and total body weight of each mouse in each group after metastases to
the liver. (D) The PCR analyses were performed for hygromycin gene using genomic DNA from parental FET cells, vector control clone and three stable
Smad7 clones as well as from the normal liver and liver metastases generated using these cell lines (top panel). Expression of Smad7 in liver metastasis was
verified by western blotting using lysates prepared from normal livers of mice injected with FET cells and vector control clone as well as liver metastases
generated by stable Smad7 clones (bottom panel).
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set al, 2005; Soini and Talvensaari-Mattila, 2006) and Claudin-4 (de
Oliveira et al, 2005; Morin, 2005; Soini and Talvensaari-Mattila,
2006) are upregulated in several cancers. To examine the
expression of these junctional proteins in Smad7-mediated liver
metastases, we observed that while E-cadherin and b-catenin were
marginally upregulated, the levels of expression of ZO-1, Claudin-
1, Claudin-4, Claudin-7, nm23, p53 and uPA were strongly elevated
in Smad7-mediated liver metastases (Figure 2C). The down-
regulation of ZO-1 leads to increased motility. ZO-1 is upregulated
in melanoma cells and that upregulation of ZO1 contributes to the
oncogenic behaviour of this tumour (Smalley et al, 2005). Another
membranous protein, nm23, is increased in highly metastatic
malignancies (do Nascimento Souza et al, 2005). The primary
function of p53 is to control checkpoints in cell cycle and to
stimulate apoptosis. Mutations in this gene produce inactive p53
proteins that accumulate in the tumour cells, and the level of
mutated protein is increased. The FET cells have a p53 mutation
(C176F) that has been shown to be elevated during the progression
of human cancers (Gayet et al, 2001). We further tested the
expression of these proteins in increasing levels of aggressiveness
(determined by the number of tumour nodules and volume of the
liver occupied by tumour) of liver metastases. The expression of
p53, E-cadherin, nm23, Claudin-4 and Claudin-7 were correlated
with the aggressiveness of liver metastasis (Figure 3A and B),
which includes number of tumour nodules, volume of the liver
occupied by tumours and liver weight. Figure 3C shows the
percentage of total number of mice, with or without liver
metastases, inoculated with vector control cells or Smad7-
expressing cells. Only one mouse (out of 18, 5.5%) from vector
control cells produce liver metastasis that covered around 20% of
the total liver. In contrast, 76% of mice from Smad7-expressing
clones produced liver metastases of different aggressiveness and
39% of these mice produced metastases that covered 460% of the
liver.
We next examined the expression of cell cycle regulatory
proteins that are differentially modulated in Smad7-mediated liver
metastases. We observed a marginal decrease in the expression
of p21
Cip1 and a marginal increase in the expression of p27
Kip1 in
liver metastases from Smad7 clones, when compared with that
from vector control clones (Figure 2D). In addition, the levels of
cyclin-dependent kinases, Cdk2 and Cdk4 and Cyclin D1 were
found to be increased in liver metastases induced by Smad7, and
this could result in the phosphorylation of pRb (Figure 2D).
Regulation of these proteins may contribute to cell proliferation in
the liver metastases.
Smad7 changes the expression pattern and localisation of
junctional proteins in liver metastases
Aberrant expression of junctional proteins such as E-cadherin and
Claudins in metastatic cancers has been reported. To test the
expression and localisation of junctional proteins in liver
metastases, IHC analyses were performed. The H&E staining
revealed poorly differentiated spindle cells in Smad7-mediated
liver metastases as shown in Figure 4A. Diffuse positive Ki67 (a cell
proliferation marker) staining was detected in Smad7-mediated
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Figure 2 Changes in protein expression in liver metastases. (A) Lysates were prepared from normal livers of mice injected with FET cells and vector
control clone as well as liver metastases generated by stable Smad7 clones. Western blot analyses were performed using antibodies against TbRII, phospho-
Smad2, Smad2, Smad3 and Smad4. b-actin was used as loading control. (B) Non-Smad pathway proteins were analysed by western blotting using antibodies
against phospho-AKT, AKT, phospho-ERK and ERK. b-actin was used as loading control. (C) Junctional proteins such as E-cadherin, b-catenin, ZO-1,
Claudin-1, Claudin-4, Claudin-7 and nm23, as well as uPA and p53 in normal and metastatic livers, were analysed by western blotting. b-actin was used as
loading control. (D) The expression of cell cycle regulatory proteins such as p21
Cip1, p27
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Smad7 induces liver metastasis
SK Halder et al
960
British Journal of Cancer (2008) 99(6), 957–965 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sliver metastases, as compared to livers from parental FET and
vector control cells (Figure 4A), suggesting the involvement of
increased cell proliferation in metastatic tumour growth. However,
we did not observe any significant change in apoptotic tunnel
positive cells between hepatocytes from parental or vector control
mice and Smad7-mediated liver metastases (Figure 4A). We
observed that phosphorylated Smad2 was predominantly localised
in the nucleus in Smad7-induced liver metastases, suggesting the
activation of TGF-b/Smad signalling, as a result of metastasis
(Figure 4B). Interestingly, we observed higher membranous
staining of E-cadherin in liver metastases induced by Smad7
(Figure 4B), whereas the localisation of b-catenin remained
unchanged (data not shown). Similarly, we observed higher
immunoreactivity of Claudin-1 and Claudin-4 in Smad7-induced
liver metastases when compared with livers of mice injected with
parental or vector control cells (Figure 4B), whereas Claudin-7 was
not changed (data not shown). These results suggest that
restoration of expression of junctional proteins may play a role
in establishing the metastatic growth at distant sites.
DISCUSSION
There is substantial evidence to demonstrate that Smad signalling
is important for TGF-b tumour suppression function, and
neoplastic transformation is often associated with the loss of this
tumour suppressor function. During cancer progression, high
levels of TGF-b can promote tumour growth in an autocrine and/
or paracrine manner through the changes that favor invasion and
metastasis. Smad4 mutation and its reduced level in colorectal
cancer are directly correlated to poor prognosis and increased
metastasis (Miyaki et al, 1999), whereas Smad7 expression is
associated with poor outcome in gastric carcinomas (Kim et al,
2004). In contrast, the tumour suppressor Smad pathway has been
shown to mediate the prometastatic function of TGF-b in the
development of breast cancer bone metastasis (Kang et al, 2005),
and dominant negative Smad3 inhibits lung metastasis of breast
cancer cells in animal models (Tian et al, 2003). In addition,
blockade of Smad pathway by overexpression of the inhibitory
Smad, Smad7 impairs bone and lung metastases (Azuma et al,
2005; Javelaud et al, 2007). Therefore, the role of Smad pathway in
TGF-b-mediated metastasis remains poorly understood and
controversial. We have previously reported that stable expression
of Smad7 in human colon adenocarcinoma FET cells induces
tumorigenicity (Halder et al, 2005), whereas Smad7 inhibits
tumorigenicity in melanoma cells (Javelaud et al, 2005). In this
report, we show that ectopic expression of Smad7 enhances
colorectal cancer metastasis to liver in a splenic injection model. In
addition, IHC analyses have suggested poorly differentiated
spindle cell morphology and higher cell proliferation in
Smad7-induced liver metastases.
Although Smad signalling has been shown to play an active role
in enhancing breast cancer and melanoma metastases in animal
models, functional inactivation of Smad signalling in human
colorectal cancer is associated with poor prognosis and distant
metastasis. This is in agreement with our present study that
blockade of Smad signalling by inhibitory Smad7 increases
tumorigenicity and liver metastasis. Human colon adenocarcino-
ma-derived FET cells are growth inhibited by TGF-b and are non-
tumorigenic. Increase in the metastatic potential of this cell line by
Smad7 may involve (1) blockade of TGF-b-mediated tumour
suppressor function by Smad7, (2) cooperation between mutated
K-Ras (in FET cells) and activated Smad2 generated as a result of
metastasis to the liver and (3) cooperation between activated
K-Ras and higher levels of Smad7. Previously, we have shown that
overexpression of Smad7 blocks TGF-b-induced growth inhibition
and apoptosis of these cells (Halder et al, 2005). Elevated levels of
TbRII expression in the liver metastases from Smad7-expressing
clones (Figure 2A) coupled with higher levels of TGF-b secretion
(data not shown) may result in phosphorylation and nuclear
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were calculated by two-way ANOVA method using GraphPad Prism 4 software. *Po0.0001; **Po0.005; ***Po0.001 by comparison with corresponding
control values were shown. (C) The graph shows the percentage of total number of mice, with or without liver metastases, inoculated with vector control
cells or Smad7-expressing cells. Percentage in the parenthesis indicates the aggressiveness in liver metastasis assessed as above.
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saccumulation of Smad2. In mouse keratinocytes during multistage
tumorigenesis, elevated levels of activated Ras are important for
the activation and nuclear accumulation of Smad2, which are
essential for inducing EMT and metastasis (Oft et al, 2002). The
FET cells have an activating mutation in K-Ras, and activation of
MAPK/ERK and AKT pathways (Figure 2B) in the liver metastases
coupled with the suppression of growth inhibitory effects of TGF-b
by Smad7 may exert a selective pressure for tumour outgrowth.
Although, our earlier studies showed that the stable expression of
Smad7 in FET cells inhibits TGF-b-induced phoshphorylation of
Smad2 (Halder et al, 2005), liver metastases resulting from these
clones show higher levels of phosphorylation and nuclear
accumulation of Smad2 (Figure 2A and B). This could be due to
the increased expression of TbRII (Figure 2A) and higher levels of
TGF-b in the liver metastases. At that point, ectopic expression of
Smad7 in the FET cells has no influence on Smad2 phosphoryla-
tion. This is consistent with the previous study that suggested
active Smad signalling with nuclear accumulation of phospho-
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Figure 4 Localisation of junctional proteins and phospho-Smad2 in Smad7-induced liver metastases. Tissues from normal livers of parental and vector
control cells injected mice and liver metastases from Smad7-expressing clones injected mice were collected 33 days after splenic injection. (A) Shows
staining with H&E, proliferation marker Ki67 and Tunnel. (B) Shows immunohistochemical staining for phospho-Smad2, E-cadherin, Claudin-1 and Claudin-4.
Pictures were taken at original magnification of 630 .
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It is possible that activated K-Ras in FET cells induces
phosphorylation and nuclear accumulation of Smad2. Subsequent
upregulation of Smad2-mediated gene expression can induce
epithelial-to-mesenchymal transition. Therefore, higher level of
activated Smad2 may cooperate with activated Ras to induce
spindle cell morphology and invasiveness of tumour cells. Smad7
cooperates with oncogenic Ras to cause malignant conversion in a
mouse model for squamous cell carcinoma, which is associated
with the blockade of normal differentiation (Liu et al, 2003). In
agreement with this, it is also possible that elevated level of Smad7
cooperates with oncogenic Ras in FET cells to induce poorly
differentiated spindle cell morphology (Figure 4A, top panel).
There is compelling evidence indicating that downregulation or
delocalisation of E-cadherin is critical for malignant progression of
epithelial tumours (Behrens, 1999). In contrast, E-cadherin
expression has also been shown to be increased in the metastatic
lesions when compared with corresponding primary site (Behrens,
1999; Kowalski et al, 2003). Cancer cells re-express E-cadherin
once they reach to distant metastasis sites and the re-expression of
E-cadherin enables cancer cells to form a metastatic deposit by
facilitating intracellular adhesion and colonisation (Kowalski et al,
2003). E-cadherin has also been shown to be upregulated in
ovarian cancer (Peralta Soler et al, 1997), renal cell carcinoma
(Tani et al, 1995) and breast cancer (Kowalski et al, 2003). In
consistent with these results, we have observed upregulation and
higher immunoreactivity of membranous E-cadherin in Smad7-
induced liver metastases (Figures 2C and 4B). In addition, the
expression of E-cadherin is enhanced with the increase in
aggressiveness of liver metastases (Figure 3A and B). Increase in
E-cadherin immunoreactivity is highly associated with a worse
prognosis of oral squamous cell carcinoma (OSCC), and the re-
expression of E-cadherin in lymph node confers advantages to
OSCC in metastasis environment (Imai et al, 2004; Hung et al,
2006). Thus, re-expression of E-cadherin in Smad7-induced liver
metastasis may play a role in the establishment and successful
growth of the metastatic cells in the liver by facilitating cell–cell
adhesion.
In most cancers, ZO-1 is typically downregulated that leads to
increased cell motility. In contrast, ZO-1 has been shown to be
upregulated in melanoma cells and is located at adherence
junction, and its upregulation contributes to the oncogenic
behaviour of this tumour (Smalley et al, 2005). Therefore,
E-cadherin and ZO-1 can function in either pro- or antioncogenic
manner when expressed in different cellular contexts. It is possible
that once in the circulation, cancer cells establish the expression
and localisation of E-cadherin and ZO-1, facilitating intercellular
adhesion and enabling the formation of cohesive tumour mass at
distant sites. Claudins are large family of integral membrane
proteins crucial for tight junction formation and cell polarity.
Disruption of tight junction barrier function and changes in
permeability properties has been shown to be associated with a
number of pathologic conditions including cancers. Previous
studies have shown that Claudin-1, Claudin-3, Claudin-4 and
Claudin-7 proteins are highly expressed in ovarian carcinoma.
These higher expressions of Claudin-1 and Claudin-7 correlated
with shorter survival (Kleinberg et al, 2008). We have observed the
upregulation of Claudin-1, Claudin-4 and Claudin-7 in Smad7-
induced liver metastases (Figures 2C and 4B), and the increased
expression of Claudin-4 and Claudin-7 is directly correlated with
the aggressiveness of metastasis as shown in Figure 3A and B. The
expression of Claudin-4 is upregulated in ovarian cancer (Honda
et al, 2006), gastric adenocarcinoma (Montgomery et al, 2006) and
colorectal cancer (de Oliveira et al, 2005). In addition, it has been
shown previously that overexpression of Claudin-4 promotes
tumorigenecity and metastasis in ovarian cancer through the
increased invasion and survival of tumour cells (Agarwal et al,
2005). Claudin-1 has been shown to be upregulated in primary and
metastatic colorectal cancer that may be important in enhancing
the tumorigenicity (Dhawan et al, 2005). These findings correlate
with our present observations. p53 is mutated in FET cells (Gayet
et al, 2001) and the upregulation of mutated p53 may contribute to
the metastatic phenotype of these cells. In addition, nm23 is
upregulated in highly metastatic malignancies (do Nascimento
Souza et al, 2005) and it is known to be directly or inversely
correlated with metastasis depending on the cancer type.
Upregulation of nm23 in Smad7-induced liver metastasis (Figures
2C and 3A, B) may be involved in the metastatic growth of Smad7-
expressing FET cells. Interestingly, none of these proteins
including E-cadherin, ZO-1, Claudins and nm23 are upregulated
in Smad7-expressing FET cells, whereas the expression of these
proteins is strongly enhanced in vivo in the liver metastases.
Recent studies have demonstrated that Smad7 expression is
induced by TGF-b, EGF and the inflammatory cytokines, such as
TNF-a and IFN-g (Afrakhte et al, 1998; Takahara et al, 2005).
Upregulation of Smad7 may induce cell proliferation through the
inhibition of p21
Cip1 (Harper et al, 1995; Robson et al, 1999) and
suppress TGF-b-mediated growth inhibition through the induction
of c-Myc (Yagi et al, 2002). The higher levels of Smad7 can induce
cell survival (Edlund et al, 2005) and inhibit apoptosis (Arnold
et al, 2004). Smad7 has been shown to induce tumorigenicity in
cooperation with activated Ras (Liu et al, 2003). Thus, increased
cell proliferation, survival and tumorigenicity, as well as the
inhibition of apoptosis, may contribute to Smad7-induced
metastatic growth in the lever (Figure 5). In conclusion, we have
established a mouse model for splenic injection of colon
adenocarcinoma FET cells that develop liver metastasis when
Smad7 is overexpressed. Smad7 not only blocks TGF-b-mediated
antitumour function, but also promotes tumour progression and
metastasis of colorectal cancer probably through the cooperation
TGF-β TGF-β Smad7
p21Cip1
Smad2/3
Smad4
Cyclin D1:Cdk4/6 
Cyclin E:Cdk2
Rb
Phosphorylation
c-Myc
Growth
induction
Tumorigenicity 
E2F
Cell cycle
progression
TNF-α
TRX
ASK1
Apoptosis
AKT
Activated
Ras
Metastasis
Survival
TGF-β EGF
IFN-γ
Figure 5 A model showing the role of Smad7 signalling in colon cancer
metastasis. The TGF-b activates TbR heterotetrameric complex, leading to
activation of the classical Smad2, Smad3 and Smad4 signalling cascade that
induces cyclin-dependent kinase inhibitor p21
Cip1 and suppresses pro-
oncogenic c-Myc expression. The p21
Cip1 expression leads to inhibition of
cyclin-dependent kinases (CDKs) and cyclins that results in hypopho-
sphorylation of Rb, repression of E2F transcriptional activity and inhibition
of cell cycle progression. Smad7 negatively regulates TGF-b/Smad signalling
pathways to induce cell proliferation by suppressing p21
Cip1 and by
induction of c-Myc. Smad7 induces cell survival through the activation of
AKT and inhibits apoptosis through the induction of TRX (thioredoxin-1)
and ASK1 (apoptosis signal-regulating kinase-1). Smad7 also cooperates
with activated Ras and induces tumorigenicity. All of these deregulations of
cell behaviour may finally contribute to metastasis. Smad7 expression is
induced by TGF-b, EGF, TNF-a and IFN-g.
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swith oncogenic Ras. Although Smad pathway has been
shown to mediate the prometastatic function of TGF-b in the
development of metastases of breast cancer (Kang et al, 2005) and
melanoma (Javelaud et al, 2007) in mouse model, our results
provide the first evidence that blockade of Smad pathway by
Smad7 in colon cancer cells increases liver metastasis. Thus,
Smad7 could be a potential target for therapeutic intervention of
colorectal cancers.
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